A phase II trial of sitravatinib, a multireceptor tyrosine kinase inhibitor, in patients with advanced well-differentiated/dedifferentiated liposarcoma.
Jay Oza, Sahil Doshi, Shing Mirn Lee, et al.
The study authors conclude that the novel, orally available, potent, small molecule RTK inhibitor sitravatinib met the predefined efficacy endpoint with 12/29 pts (41%) progression-free at 12 weeks. This indicates a clinically meaningful activity which is potentially superior to pazopanib. Sitravatinib was well tolerated. Further study of S in WD/DD LPS is warranted. Clinical trial information: NCT02978859
Damon R. Reed, Sant P. Chawla, Bhuvana Setty, et al.
The study authors conclude that Seclidemstat -a novel, selective, reversible oral LSD1 inhibitor - has a manageable safety profile with proof-of-concept preliminary activity in heavily pretreated patients with relapsed/refractory ES. A phase 2 expansion of seclidemstat as single agent and in combination with chemotherapy is planned in ES and other sarcomas that share similar translocations. Clinical trial information: NCT03600649
Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
Margaret von Mehren, Sujana Movva, Elizabeth A. Handorf, et al.
The study authors conclude that the ribociclib plus everolimus combination showed activity in dedifferentiated liposarcoma with a prolonged stable disease (>16 weeks). This met the primary protocol endpoint. Partial responses were also observed. The treatment was well tolerated with acceptable side effects. Clinical trial information: NCT03114527
Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.
Chang Gon Kim, Jin-Hee Ahn, Jeong Eun Kim, et al.
The study authors conclude that Eribulin and gemcitabine showed promising activity and manageable safety profile in patients with soft-tissue sarcoma of liposarcoma and leiomyosarcoma histology. Clinical trial information: NCT03810976
Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).
Steven Attia, Victor Manuel Villalobos, Nadia Hindi, et al.
The study authors observed no statistically significant difference in overall survival between the two arms in the olaratumab-naïve population. However, the combination of olaratumab, gemcitabine and docetaxel demonstrated favorable progression-free and overall survival in the olaratumab-pretreated cohort, and an objective response rate in both cohorts (without statistical significance). For olaratumab-naïve patients, the study revealed a clinically meaningful progression-free survival improvement. Clinical trial information: NCT02659020
Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.
Roberta Sanfilippo, Richard L Hayward, Jammbe Musoro, et al.
The study authors conclude that EORTC 1202 met its primary endpoint, with 21/38 pts (55%) being progression-free at 12 weeks. This trial confirms the activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma. The results look interesting if compared to the other available options and experimental drugs recently reported in this patient population. Clinical trial information: NCT01913652
Abdul Rafeh Naqash, Geraldine Helen O'Sullivan Coyne, Nancy Moore, et al.
The study authors conclude that atezolizumab is well tolerated and demonstrates promising single-agent activity with durable responses in advanced ASPS. Preliminary tumor biomarker analysis which confirm the presence of multiple PD-1/PD-L1 immune checkpoint (IC) components indicate advanced ASPS being an ideal candidate for therapeutic IC inhibition. Clinical trial information: NCT03141684
High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.
Jean-Yves Blay, Nicolas Penel, Isabelle Laure Ray-Coquard, et al.
The study authors conclude that Pembrolizumab is safe and well tolerateted. The AcSé study reports high levels of response rate and prolonged activity in selected subtypes of rare sarcomas. Clinical trial information: NCT03012620
Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.
Sandra P. D'Angelo, Mihaela Druta, Brian Andrew Van Tine, et al.
The study authors conclude that A single lete-cel infusion - an autologous T-cell therapy - after high-dose lymphodepletion showed antitumor activity in advanced MRCLS and a manageable safety profile consistent with other lete-cel studies. This active trial is no longer recruiting. Clinical trial information: NCT02992743
A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).
Olubukola Ayodele, Ben X Wang, Thomas D Pfister, et al.
The study authors conclude that durvalumab plus olaparib or durvalumab plus cediranib resulted in stable disease in 30% of patients, mostly on arm A (D+O). Clinical trial information: NCT03851614
Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.
Michael J Wagner, Matthew Ingham, Corrie Painter, et al.
The study authors conclude that their study is the largest cohort of patients with sarcoma and COVID-19 to date. These patients have high rates of complications from COVID-19. Worse outcome are seen in older patients, and patients with poor performance status, and patients recently receiving systemic cancer therapy, and those with lung metastases.
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
Yoshitaka Honma, Yukinori Kurokawa, Akira Sawaki, et al.
The study authors conclude that their trial demonstrated that Pimitespib (PIM) - a novel class of orally active selective HSP90 inhibitors - for the first time significantly improved progression-free and overall survival prolongation in patients with advanced GIST refractory to IM, SU, and REG. The drug was tolerated and AEs were manageable. The authors suggest that with this different action PIM has the potential to be a new standard treatment in GIST. Clinical trial information: JapicCTI-184094.